SCHEMBL17697819

SCHEMBL17697819

Cc1cc2c(cc1-c1ccc(NC(=O)c3c(F)cccc3F)cn1)OCC(=O)N2C

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 3/20 0.46
▸ RAB9A P51151 3/20 0.46
▸ IL2 P60568 9/20 0.45
▸ MALT1 Q9UDY8 1/20 0.43
▸ CRACR2A Q9BSW2 2/20 0.43
▸ MAP3K5 Q99683 1/20 0.43
▸ TP53 P04637 2/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ WNT3A P56704 1/20 0.41
▸ PTGER3 P43115 1/20 0.41
▸ STIM1 Q13586 2/20 0.40
▸ ORAI1 Q96D31 2/20 0.40
▸ TNF P01375 1/20 0.40
▸ GRM1 Q13255 1/20 0.39
▸ GRM4 Q14833 1/20 0.39
▸ ORAI2 Q96SN7 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17697815 0.89 CRACR2A (0.47) NPC1RAB9AIL2MALT1CRACR2A
SCHEMBL17697823 0.88 IL2 (0.56) IL2MALT1MAP3K5PTGER3STIM1
SCHEMBL16362061 0.86 IL2 (0.54) NPC1RAB9AIL2MALT1MAP3K5
SCHEMBL17697813 0.83 IL2 (0.54) IL2MAP3K5PTGER3STIM1ORAI1
SCHEMBL16362444 0.83 IL2 (0.54) NPC1RAB9AIL2MALT1MAP3K5
SCHEMBL12155550 0.82 RAB9A (0.60) NPC1RAB9AIL2CRACR2ATP53
SCHEMBL12155575 0.79 NPC1 (0.55) NPC1RAB9AIL2CRACR2ATP53
SCHEMBL17697811 0.79 IL2 (0.48) IL2CRACR2AMAP3K5STIM1ORAI1
SCHEMBL16362099 0.79 CRACR2A (0.45) NPC1RAB9AIL2CRACR2ATP53
SCHEMBL16362057 0.78 IL2 (0.56) NPC1RAB9AIL2MALT1MAP3K5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9725463-B2 Substituted heterocyclic compounds as CRAC modulators LUPIN LIMITED (IN) 2017-08-08 — — US claimed
US-20160145268-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS LUPIN LIMITED (IN) 2016-05-26 — — US claimed
EP-3010586-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS Lupin Limited (IN) 2016-04-27 — — EP claimed
US-9725463-B2 Substituted heterocyclic compounds as CRAC modulators LUPIN LIMITED (IN) 2017-08-08 — — US disclosed
US-9725463-B2 Substituted heterocyclic compounds as CRAC modulators LUPIN LIMITED (IN) 2017-08-08 — — US disclosed
US-9725463-B2 Substituted heterocyclic compounds as CRAC modulators LUPIN LIMITED (IN) 2017-08-08 — — US disclosed
US-20160145268-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS LUPIN LIMITED (IN) 2016-05-26 — — US disclosed
US-20160145268-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS LUPIN LIMITED (IN) 2016-05-26 — — US disclosed
US-20160145268-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS LUPIN LIMITED (IN) 2016-05-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160145268-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS RYR2, NR2C2, CACNA1E NPC1 1879/4885RAB9A 1720/4885IL2 2831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback